Compare Novo Nordisk A/S (NVO) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs AT&T Inc. — how do they compare? Novo Nordisk A/S trades at $38.15 (market cap $165.31B), while AT&T Inc. trades at $22.96 (market cap $170.42B). The key difference: Novo Nordisk A/S and AT&T Inc. are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and AT&T Inc. for 118 Days on average.
| NVO | T | |
|---|---|---|
Market Cap | $165.31B | $170.42B |
Volume | 11,432,838 | 50,780,036 |
Sector | Health | Media |
52-Week High | $63.98 | $29.10 |
52-Week Low | $35.29 | $20.49 |
Typical Hold Time | 116 Days | 118 Days |
Enterprise Value | $179.56B | $315.74B |
Dividend Yield | 4.71% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
AT&T (T) trades at $24.475, up 0.2% on the day, with a bearish technical signal but strong fundamentals including a low P/E of 8.08 and robust profitability. Recent earnings have consistently beaten estimates, and the company maintains a solid dividend. Cash flow improved significantly in 2025 to $15.12B net, while debt levels remain manageable. News highlights a $3B fiber deal with Corning and joint ventures to expand coverage.
The stock appears undervalued with a consensus price target of $27.61, offering a 13% upside. Key opportunities include fiber expansion and wireless growth, but risks involve intense competition, high debt, and potential dividend sustainability concerns. Analyst sentiment is mixed with 44% buy ratings, suggesting cautious optimism for long-term income investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
